Johnson & Johnson Reserves $600M To Settle Risperdal, Invega, Natrecor Civil Cases

Johnson & Johnson Reserves $600M To Settle Risperdal, Invega, Natrecor Civil Cases

NEW BRUNSWICK, N.J. - Johnson & Johnson (J&J) expects to incur a special charge against earnings of about $600 million in the second quarter for the potential settlement of civil litigation related to Risperdal, Invega, Natrecor and Omnicare Inc., according to a Form 8-K report filed June 8 with the U.S. Securities and Exchange Commission.

Find full version on lexis Advance®
Access this news story on lexis.com®